The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Creative Commons License

Kocaturk E., SALMAN A., Cherrez-Ojeda I., Criado P. R., Peter J., Comert-Ozer E., ...Daha Fazla

ALLERGY, cilt.76, sa.3, ss.816-830, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 76 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/all.14687
  • Dergi Adı: ALLERGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.816-830
  • Anahtar Kelimeler: chronic urticaria, COVID-19, cyclosporine, omalizumab, pandemic, SARS-CoV-2, treatment, UCARE, ASSOCIATION, INFECTIONS, OMALIZUMAB, STRESS, SERUM
  • İstanbul Üniversitesi Adresli: Evet

Özet

Introduction The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown.